<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03529045</url>
  </required_header>
  <id_info>
    <org_study_id>LNN-801</org_study_id>
    <nct_id>NCT03529045</nct_id>
  </id_info>
  <brief_title>Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System.</brief_title>
  <acronym>CORE-VNS</acronym>
  <official_title>CORE-VNS: Comprehensive Outcomes Registry in Subjects With Epilepsy Treated With Vagus Nerve Stimulation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LivaNova</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LivaNova</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter global post-market registry of subjects diagnosed with drug resistant epilepsy
      and treated with the VNS Therapy System.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this registry is to evaluate clinical outcome and safety data in subjects with
      drug resistant epilepsy treated with the VNS Therapy System. The study will collect outcomes
      for subjects treated with VNS Therapy in a real-world setting.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 5, 2018</start_date>
  <completion_date type="Anticipated">March 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2026</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Seizure Frequency</measure>
    <time_frame>Baseline, 3, 6, 12, 24, and 36 months after implant; long term follow-up data through 60 months may be collected, if applicable</time_frame>
    <description>The average seizure frequency per month over the last 3 months (by type) will be collected</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Seizure Free Period</measure>
    <time_frame>Baseline, 3, 6, 12, 24, and 36 months after implant; long term follow-up data through 60 months may be collected, if applicable</time_frame>
    <description>The maximum seizure free period over the last 3 months will be collected</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seizure Severity</measure>
    <time_frame>Baseline, 3, 6, 12, 24, and 36 months after implant; long term follow-up data through 60 months may be collected, if applicable</time_frame>
    <description>Seizure severity is a categorical outcome and will be rated by the subject using the following categories: Very mild, Mild, Moderate, Severe, Very Severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-ictal Severity</measure>
    <time_frame>Baseline, 3, 6, 12, 24, and 36 months after implant; long term follow-up data through 60 months may be collected, if applicable</time_frame>
    <description>Seizure severity is a categorical outcome and will be rated by the subject using the following categories: Very mild, Mild, Moderate, Severe, Very Severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Baseline, 3, 6, 12, 24, and 36 months after implant; long term follow-up data through 60 months may be collected, if applicable</time_frame>
    <description>Quality of life is a categorical outcome and will be rated by the subject using the following categories: Very good: could hardly be better, Pretty good, Good and bad parts about equal, Pretty bad, Very bad: could hardly be worse</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of Sleep</measure>
    <time_frame>Baseline, 3, 6, 12, 24, and 36 months after implant; long term follow-up data through 60 months may be collected, if applicable</time_frame>
    <description>Quality of sleep will be reported using the Pittsburgh Sleep Quality Index for subjects 18 years and older and using the Children's Sleep Habit Questionnaire for subjects 2-17 years old; quality of sleep will not be assessed in children under 2 years old</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-epileptic Drug Use</measure>
    <time_frame>Baseline, 3, 6, 12, 24, and 36 months after implant; long term follow-up data through 60 months may be collected, if applicable</time_frame>
    <description>The name and dose of anti-epileptic drugs used will be collected on a case report form</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rescue Drug Use</measure>
    <time_frame>Baseline, 3, 6, 12, 24, and 36 months after implant; long term follow-up data through 60 months may be collected, if applicable</time_frame>
    <description>The number of times a rescue drug was used will be collected</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seizure Related Emergency Department Visits</measure>
    <time_frame>Baseline, 3, 6, 12, 24, and 36 months after implant; long term follow-up data through 60 months may be collected, if applicable</time_frame>
    <description>The number of times a patient had a seizure related emergency department (ED) visit will be collected</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seizure Related Hospitalizations</measure>
    <time_frame>Baseline, 3, 6, 12, 24, and 36 months after implant; long term follow-up data through 60 months may be collected, if applicable</time_frame>
    <description>The number of times a patient had a seizure related inpatient hospitalization and the length of each stay will be collected</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Epilepsy</condition>
  <condition>Seizures</condition>
  <condition>Drug Resistant Epilepsy</condition>
  <arm_group>
    <arm_group_label>VNS Therapy</arm_group_label>
    <description>Any approved VNS Therapy System (according to local regulations) may be used in this registry.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vagus Nerve Stimulation (VNS) Therapy</intervention_name>
    <description>The VNS Therapy System is a commercially available device that will be used by licensed medical practitioners trained in the use of VNS Therapy, per the practitioners' medical judgement.</description>
    <arm_group_label>VNS Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects diagnosed with drug resistant epilepsy and treated with the VNS Therapy System.
        Eligible subjects include those receiving VNS Therapy for the first time, as well as those
        that are being re-implanted with VNS
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of drug resistant epilepsy treated with VNS Therapy. Eligible
             subjects include those not previously treated with VNS Therapy as well as subjects
             receiving replacement generators.

          -  Able and willing to comply with the frequency of study visits.

          -  Subject, or legal guardian, understands study procedures and voluntarily signs an
             informed consent in accordance with institutional policies. In the event that the
             subject is under the age of 18, the subject may also be required (per EC/IRB) to sign
             an assent affirming their agreement to participate.

        Exclusion Criteria:

        • There are no exclusion criteria in this study. Investigators should refer to the local
        instructions for use for VNS Therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Jones, MS</last_name>
    <role>Study Director</role>
    <affiliation>LivaNova USA, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ljubomir Manola, PhD</last_name>
    <phone>+32 2 715 93 12</phone>
    <email>ljubomir.manola@livanova.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeff Way</last_name>
    <phone>281-228-7394</phone>
    <email>jeffrey.way@livanova.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hawaii Pacific Neuroscience</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Chao</last_name>
      <phone>808-564-6142</phone>
      <email>cchao@hawaiineuroscience.com</email>
    </contact>
    <investigator>
      <last_name>Kore Liow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Onsite Clinical</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brooke Withers</last_name>
      <phone>704-600-7764</phone>
      <email>bwithers@onsiteclinical.com</email>
    </contact>
    <investigator>
      <last_name>Robert Nahouraii, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989 May;28(2):193-213.</citation>
    <PMID>2748771</PMID>
  </reference>
  <reference>
    <citation>Ekinci O, Isik U, Gunes S, Ekinci N. Understanding sleep problems in children with epilepsy: Associations with quality of life, Attention-Deficit Hyperactivity Disorder and maternal emotional symptoms. Seizure. 2016 Aug;40:108-13. doi: 10.1016/j.seizure.2016.06.011. Epub 2016 Jun 27.</citation>
    <PMID>27394056</PMID>
  </reference>
  <reference>
    <citation>Goodlin-Jones BL, Sitnick SL, Tang K, Liu J, Anders TF. The Children's Sleep Habits Questionnaire in toddlers and preschool children. J Dev Behav Pediatr. 2008 Apr;29(2):82-88.</citation>
    <PMID>18478627</PMID>
  </reference>
  <reference>
    <citation>Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000 Feb 3;342(5):314-9.</citation>
    <PMID>10660394</PMID>
  </reference>
  <reference>
    <citation>Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, Moshé SL, Perucca E, Wiebe S, French J. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010 Jun;51(6):1069-77. doi: 10.1111/j.1528-1167.2009.02397.x. Epub 2009 Nov 3. Erratum in: Epilepsia. 2010 Sep;51(9):1922.</citation>
    <PMID>19889013</PMID>
  </reference>
  <reference>
    <citation>Owens JA, Spirito A, McGuinn M. The Children's Sleep Habits Questionnaire (CSHQ): psychometric properties of a survey instrument for school-aged children. Sleep. 2000 Dec 15;23(8):1043-51.</citation>
    <PMID>11145319</PMID>
  </reference>
  <reference>
    <citation>von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007 Oct 20;370(9596):1453-7.</citation>
    <PMID>18064739</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2018</study_first_submitted>
  <study_first_submitted_qc>May 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2018</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VNS</keyword>
  <keyword>VNS Therapy</keyword>
  <keyword>Vagus Nerve Stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Seizures</mesh_term>
    <mesh_term>Drug Resistant Epilepsy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

